Linda Zhong
Kowloon Tong, Kowloon, Hong Kong
Location status: Recruiting
NCT Number: NCT06633666
In this study, a 12-week pragmatic, randomized, double-blinded clinical trial will be conducted to evaluate the efficacy of acupuncture for the treatment of long Covid neuropsychiatric symptoms and provide reference for clinical non-drug treatment.
Interested in participating?
Request Info18 year–80 year
All sexes
Interventional
Not applicable
Kowloon Tong, Kowloon, Hong Kong
Location status: Recruiting
This is a pragmatic, randomized, double-blinded clinical trial on acupuncture for treating neuropsychiatric symptoms in long Covid patients. A total of 160 participants will be diagnosed by a registered Chinese medicine practitioner and randomly assigned to the acupuncture and the control group with a 1:1 ratio. The acupuncture group will receive 24 sessions of interventions during a 12-week treatment duration (2 sessions per week) and will be followed up at week 18. The control group will only receive conventional therapy.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: At baseline (before intervention), at 6, 12 weeks (the end of intervention), at 18 weeks (follow-up)
The MMSE can evaluate of five different domains of cognitive functions: (1) Orientation, with a maximum of 10 points, (2) Memory, with a maximum of 6 points, (3) Attention and calculation, with a maximum of 5 points, (4) Language, with a maximum of 8 points, and (5) Design copying, with a maximum of 1 point. It has a maximum score of 30, with MMSE score denotes severity of cognitive impairment as follows; mild: MMSE 21 to 24, moderate: MMSE 10 to 20, severe: MMSE less than 10.
Time frame: At baseline (before intervention), at 6, 12 weeks (the end of intervention), at 18 weeks (follow-up)
The scale has a total of 21 questions, with an overall score of 63, 14-19 being mild depression, 20-28 being moderate depression, and above 29 being severe depression.
Time frame: At baseline (before intervention), at 6, 12 weeks (the end of intervention), at 18 weeks (follow-up)
The Insomnia Severity Index in Chinese includes 5 questions to assess the severity and impact of insomnia, on an 0 to 4 scale, with the higher score reflecting worse insomnia symptoms.
Time frame: At baseline (before intervention), at 6, 12 weeks (the end of intervention), at 18 weeks (follow-up)
BFI-T form is to assess the severity of fatigue and the impact of fatigue on daily functioning. Scoring Respondents rate each item on a 0-10 numeric scale, with 0 meaning "no fatigue" and 10 meaning "fatigue as bad as you can imagine." Scores are categorized as Mild (1-3), Moderate (4-6), and Severe (7-10).
Time frame: At baseline (before intervention), at 6, 12 weeks (the end of intervention), at 18 weeks (follow-up)
A validated 24-item scale used to assess depressive severity across emotional, cognitive, and somatic domains. Scores range as follows: 0-7 (normal), 8-17 (mild depression), 18-24 (moderate depression), and ≥25 (severe depression), with higher scores indicating more severe depressive symptoms.
Time frame: At baseline (before intervention), at 6, 12 weeks (the end of intervention), at 18 weeks (follow-up)
A 14-item scale for assessing anxiety symptoms across somatic and psychological domains. Scoring ranges are: 0-7 (normal), 8-14 (mild anxiety), 15-28 (moderate anxiety), and ≥29 (severe anxiety), with higher scores indicating greater anxiety severity.
Time frame: At baseline (before intervention), at 6, 12 weeks (the end of intervention), at 18 weeks (follow-up)
A TCM-specific symptom scale following "Guidelines for Clinical Research on New Chinese Medicine," assessing syndrome severity based on TCM diagnostics. Scores quantify symptom burden with defined thresholds for mild, moderate, and severe syndrome levels, enabling standardized assessment of TCM syndrome differentiation.
Contact information is provided by the study sponsor or research team.
Hong Kong Baptist University
Other
Acupuncture for Long COVID Neuropsychiatric Symptoms: a Pragmatic,Randomized Clinical Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07189936
Autonomic Nervous System Diseases, COVID-19
Nashville, Tennessee, United States
View Trial DetailsNCT07140094
COVID Long-Haul, COVID-19
New York, United States
View Trial DetailsNCT05741112
Autonomic Nervous System Diseases, COVID-19
La Jolla, California, United States
View Trial DetailsNCT05582512
COVID-19, COVID-19 Pneumonia
Taipei, Chung Cheng District, Taiwan
View Trial Details